Locus Biosciences
Locus Biosciences is a clinical-stage pharmaceutical company, founded in 2015 and based in Research Triangle Park, North Carolina which to develop phage therapies based on CRISPR–Cas3 gene editing technology, as opposed to the more commonly used CRISPR-Case9, delivered by engineered bacteriophages. The intended therapeutic targets are antibiotic-resistant bacterial infections.
Link from a Wikipage to another Wikipage
primaryTopic
Locus Biosciences
Locus Biosciences is a clinical-stage pharmaceutical company, founded in 2015 and based in Research Triangle Park, North Carolina which to develop phage therapies based on CRISPR–Cas3 gene editing technology, as opposed to the more commonly used CRISPR-Case9, delivered by engineered bacteriophages. The intended therapeutic targets are antibiotic-resistant bacterial infections.
has abstract
Locus Biosciences is a clinica ...... esistant bacterial infections.
@en
founding date
2015-05-22
founding year
industry
location city
number of employees
Wikipage page ID
60,171,936
page length (characters) of wiki page
Wikipage revision ID
1,013,956,329
Link from a Wikipage to another Wikipage
brands
crPhage
@en
founded
2015-05-22
founders
@en
Ahmed Gomaa
@en
Charles Gersbach
@en
Chase Beisel
@en
Dave Ousterout
@en
Nick Taylor
@en
Paul Garofolo
@en
Rodolphe Barrangou
@en
hq location city
Morrisville, North Carolina
@en
hq location country
United States
@en
industry
logo
@en
name
Locus Biosciences
@en
num employees
type
Privately held company
@en
wikiPageUsesTemplate
subject
comment
Locus Biosciences is a clinica ...... esistant bacterial infections.
@en
label
Locus Biosciences
@en
sameAs
wasDerivedFrom
isPrimaryTopicOf
name
Locus Biosciences
@en